+91-8668442535
Home / Biotechnology / Recombinan

Recombinant Vaccines Market By Disease (Infectious Diseases, Cancer) - Growth, Future Prospects, And Competitive Analysis, 2017 -2025

Vaccines play a significant role in the prevention and control of different forms of infectious diseases. In the previous years, killed or attenuated vaccines were used, gradually transitioning to a recombinant subunit approach in the last two decades. The use of recombinant technologies in the production of subunit vaccines simplifies, secures, and reduces costs. A recombinant vaccine is manufactured using recombinant DNA technology, and it offers the prime advantage that there is a complete absence of pathogens during the production and purification procedures, thus making the production procedure safer.

The research study titled "Recombinant Vaccines Market: Growth, Future Prospects, and Competitive Analysis, 2017–2025" covers in-depth information related to the recombinant vaccines market. The research study provides a comprehensive analysis based on different market segments, such as disease type and geography. Infectious diseases and cancer are covered in the disease type segment analysis. The infectious diseases segment is further classified as hepatitis B infection, herpes zoster infection, influenza infection, and other infectious diseases.

The global recombinant vaccines market is made up of North America (including the United States and Canada), Europe (including the United Kingdom and Germany), Asia Pacific (including Japan and China), Latin America (including Mexico and Brazil), and the Middle East and Africa (GCC). The market size and forecast for these regions, along with their cross-sectional segmentation, are provided in this report for the considered period. The regional markets are further studied in terms of major country-specific markets.

Quantitative data and qualitative information are included in this report for further understanding of the current market situation and possible future scenarios. Information such as market dynamics (drivers, opportunities, and challenges) gives a detailed idea of the current developments in the global recombinant vaccine market. The report also includes competitive profiling of prominent players, attractive investment propositions, and market positions of key leaders involved in the global recombinant vaccine market to assist with strategic decisions about the recombinant vaccine market.

Based on disease type, the global recombinant vaccine market is segmented as follows:

Infectious diseases

  • Hepatitis B infection
  • herpes zoster infection
  • Influenza Infection
  • Other Infectious Diseases
  • Cancer

According to the World Health Organization (WHO), the vaccine market is essentially dependent on the governments of industrialized and developing countries, the private sector, and various regulatory and advisory bodies. Recombinant DNA vaccines are third-generation vaccines produced by using recombinant DNA technology or genetic engineering to prevent different diseases. These vaccines are more advanced than conventional vaccines in preventing diseases such as hepatitis, herpes, papillomavirus infection, influenza, etc. The recombinant vaccines market will grow significantly during the forecast period as it involves a novel method to elicit humoral as well as cellular immune responses, reduced risk of pathogenicity, and an easier approach for large-scale production.

In 1986, the first hepatitis B recombinant vaccine was approved in the United States. Currently, hepatitis B infection is a major revenue-generating segment, as the hepatitis B vaccine is included in the World Health Organization's list of essential medicines. Moreover, the Centers for Disease Control and Prevention (CDC), the American Academy of Pediatrics (AAP), and the American College of Obstetricians and Gynecologists (ACOG) also strongly recommend hepatitis B vaccination. Currently, hepatitis B recombinant vaccine revenue is largely generated by Engerix-B, Recombivax-HB, Pediarix, Comvax, Twinrix, etc. GlaxoSmithKline and Merck are the key players in the hepatitis B vaccine market. Promising pipeline vaccines such as VPM1002 (BCG), EBOV-GP (Ebola), Shingrix (Herpes Zoster), GSK-2189242A (pneumococcal infections), ID-93 (tuberculosis), PROSTVAC-VF (prostate cancer), etc. are expected to further assist the market's growth during the forecast period of 2017–2025.

The recombinant vaccines market is divided into three segments for the purposes of this study:

  • North America
    • United States
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • Rest of Europe
  • Latin America
    • Brazil
    • Mexico
    • rest of Latin America
  • Middle East and Africa
    • GCC
    • Rest of the Middle East and Africa

Recombinant vaccines are a more advanced, efficient, and safe technique produced by using recombinant DNA technology or genetic engineering. According to the World Health Organization (WHO), demand for vaccines mainly depends on the governments of countries, the pooling of procurement agencies, the proliferation of private players, and the presence and involvement of various regulatory and regulatory bodies overseeing vaccine safety and quality. The WHO also estimated that high-income countries such as the United States, the United Kingdom, France, etc., contribute over 80% of vaccine revenue due to the faster adoption of newer vaccines and higher costs. According to research, North America held the largest market share in 2016 due to higher recombinant vaccine costs, increased healthcare awareness, the strong recommendation of immunization programs, faster implementation of newer vaccines, and widespread availability of FDA-approved recombinant vaccines for various indications. Favorable R&D activities and the strong presence of pipeline vaccines such as VPM1002, EBOV-GP, Shingrix, GSK-2189242A, ID-93, PROSTVAC-VF, etc., would further assist the recombinant vaccine market's growth in North America. It is also estimated that Asia Pacific will show the fastest market growth during the forecast period due to increasing healthcare awareness and rising government initiatives in the immunization program. According to the WHO, middle- and low-income countries generate approximately 18% of the value of total global vaccine sales, constituting around 80% of the annual volume sold. The WHO estimated that vaccine demand from the private sector is relatively small, i.e., about 5–10% of the total vaccine sales in developing countries.

Frequently Asked Questions:

The market for Recombinant Vaccines is expected to reach US$ XX Mn in 2025.

The Recombinant Vaccines market is expected to see significant CAGR growth over the coming years,at 6.4%.

The report is forecasted from 2017-2025.

The base year of this report is 2016.

Bharat Biotech,GlaxoSmithKline Plc., MedImmune, LLC, Merck & Co. Inc.Novartis AG are some of the major players in the global market.

Choose License Type
Trusted By
Godaddy
Published Date:  Nov 2017
Category:  Biotechnology
Report ID:   58819
Report Format:   PDF
Pages:   120
Rating:    4.8 (80)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support